Back to Search Start Over

Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism: A Randomized Trial

Authors :
Jara Palomares, Luis [0000-0002-4125-3376]
Otero Candelera, Remedios [0000-0002-2265-1221]
Jiménez, David [0000-0002-4571-7721]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
Barrios, Deisy
Durán, Diego
Rodríguez, Carmen
Moisés, Jorge
Retegui, Ana
Lobo, José Luis
López, Raquel
Chasco-Eguilaz, Leyre
Jara Palomares, Luis
Muriel, Alfonso
Otero Candelera, Remedios
Ruiz-Artacho, Pedro
Monreal, Manuel
Bikdeli, Behnood
Jiménez, David
Air vs Oxygen for Intermediate-Risk Pulmonary Embolism Investigators
Jara Palomares, Luis [0000-0002-4125-3376]
Otero Candelera, Remedios [0000-0002-2265-1221]
Jiménez, David [0000-0002-4571-7721]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
Barrios, Deisy
Durán, Diego
Rodríguez, Carmen
Moisés, Jorge
Retegui, Ana
Lobo, José Luis
López, Raquel
Chasco-Eguilaz, Leyre
Jara Palomares, Luis
Muriel, Alfonso
Otero Candelera, Remedios
Ruiz-Artacho, Pedro
Monreal, Manuel
Bikdeli, Behnood
Jiménez, David
Air vs Oxygen for Intermediate-Risk Pulmonary Embolism Investigators
Publication Year :
2024

Abstract

[Background] The effect of supplemental oxygen therapy in patients with intermediate-risk pulmonary embolism (PE) who do not have hypoxemia at baseline is uncertain.<br />[Research Question] Does supplemental oxygen improve echocardiographic parameters in nonhypoxemic patients with intermediate-risk PE?<br />[Study Design And Methods] This pilot trial randomly assigned nonhypoxemic patients with stable PE and echocardiographic right ventricle (RV) enlargement to receive anticoagulation plus supplemental oxygen for the first 48 h vs anticoagulation alone. The primary outcome was normal echocardiographic RV size 48 h after randomization. Secondary efficacy outcomes were the numerical change in the RV to left ventricle (LV) diameter ratio measured 48 h and 7 days after randomization with respect to the baseline ratio measured at inclusion.<br />[Results] The study was stopped prematurely because of the COVID-19 pandemic after recruiting 70 patients (mean ± SD age, 67.3 ± 16.1 years; 36 female [51.4%]) with primary outcome data. Forty-eight h after randomization, normalization of the RV size occurred in 14 of the 33 patients (42.4%) assigned to oxygen and in eight of the 37 patients (21.6%) assigned to ambient air (P = .08). In the oxygen group, the mean RV to LV ratio was reduced from 1.28 ± 0.28 at baseline to 1.01 ± 0.16 at 48 h (P < .001); in the ambient air group, mean RV to LV ratios were 1.21 ± 0.18 at baseline and 1.08 ± 0.19 at 48 h (P < .01). At 90 days, one major bleeding event and one death (both in the ambient air group) had occurred.<br />[Interpretation] In analyses limited by a small number of enrollees, compared with ambient air, supplemental oxygen did not significantly increase the proportion of patients with nonhypoxemic intermediate-risk PE whose RV to LV ratio normalized after 48 h of treatment. This pilot trial showed improvement in some ancillary efficacy outcomes and provides support for a definitive clinical outcomes trial.<br />[Trial Registry] ClinicalTrials.gov; No.: NCT04003116; URL: www.clinicaltrials.gov

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1442728529
Document Type :
Electronic Resource